You are here
Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
CAMBRIDGE, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has named Glenn Goddard its executive vice president and chief financial officer. Mr. Goddard will be a member of Intellia’s executive management team and will oversee all financial functions and investor relations, as well as information technologies and facilities.
“Glenn’s background in emerging biotech companies and experience as a financial and business leader will be great assets to our growing company, and will be important as Intellia implements its full-spectrum genome editing strategy,” said Intellia President and Chief Executive Officer John Leonard, M.D. “As Intellia moves toward the clinic and transitions from an early- to mid-stage biotech company, we are pleased to further augment our in-house expertise with Glenn’s proven track record of being part of leadership teams that have successfully guided therapeutics for genetic diseases from preclinical efforts through clinical development.”
Mr. Goddard joins Intellia with nearly 20 years of experience leading financial and business support operations for biotechnology companies, including strategic planning, fundraising, investor relations, financial reporting and controls, information technologies and facilities. Before Intellia, Mr. Goddard was the chief financial officer at Generation Bio Company, where he led all financial functions, investor relations, information technologies and facilities. Previously, as the senior vice president of finance and principal financial officer at Agios Pharmaceuticals, Mr. Goddard helped lead the transition from an early-stage research company to a commercial-ready organization, including progressing the company’s lead candidate through clinical trials.
Additionally, he led Agios’ strategic financing efforts, raising more than $700 million in equity financings. Prior to Agios, Mr. Goddard held various senior-level financial management positions at both Archemix, a privately held oligonucleotide platform-based biopharmaceutical company, and Immunogen, a publicly traded oncology-focused biopharmaceutical company. Mr. Goddard earned a bachelor of science in accountancy from Bentley College and is a certified public accountant.
“I look forward to joining Intellia at this exciting time and helping the team achieve our mission of developing curative medicines based on its novel CRISPR/Cas9 platform,” said Mr. Goddard.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding our growth as a company and the anticipated contribution of the members of our board of directors and our executives to our operations and progress.
Any forward-looking statements in this presentation are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain our intellectual property position; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies will not be predictive of future results in connection with future studies; the risk that Intellia’s collaborations with Novartis or Regeneron or its other ex vivo collaborations will not continue or will not be successful; and risks related to the competitive landscape. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. All information in this presentation is as of the date of the release, and Intellia Therapeutics undertakes no duty to update this information unless required by law.
Jennifer Mound Smoter
Senior Vice President
External Affairs & Communications
External Affairs & Communications